Sabahattin Kaymakoglu

Sabahattin Kaymakoglu

Auto-generated profile, based on publicly available information

Sabahattin Kaymakoglu

Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
BBBulent Baran
Bulent Baran
OSOzlem Mutluay Soyer
Ozlem Mutluay Soyer
AOAsli Cifcibasi Ormeci
Asli Cifcibasi Ormeci
SGSuut Gokturk
Suut Gokturk
SESami Evirgen
Sami Evirgen
SKSabahattin Kaymakoglu
Sabahattin Kaymakoglu
We evaluated the efficacy of tenofovir disoproxil fumarate (TDF) in patients with lamivudine failure (LAM-F) in comparison with that in nucleoside/nucleotide analogue (NA)-naïve patients with chronic hepatitis B (CHB). The criteria for inclusion were being NA naïve or having previous LAM-F and receiving TDF therapy for at least 6 months. Biochemical and virological tests were performed at the baseline, at 3-month intervals in the first year, and every 6 months thereafter. The primary outcome measure for efficacy was a complete virological response (CVR), defined as an HBV DNA level of <20 IU/ml. CVR rates were calculated by Kaplan-Meier analysis, and a multivariate Cox proportional-hazard model was generated in order to find predictive factors independently associated with the time to a CVR. We included 197 patients in the study (136 males; mean age, 43 ± 12 years; 105 patients were NA naïve). Sixty-five patients had hepatitis B e antigen (HBeAg)-positive CHB. The median duration of TDF treatment was 29 (range, 6 to 52) months. Seventy-one patients (77%) in the LAM-F group were treated with TDF add-on therapy. The CVR rates of the NA-naïve and LAM-F groups were comparable in HBeAg-negative (94% versus 96% at month 36,P= 0.10) and HBeAg-positive patients (67% versus 83% at month 36,P= 0.48). According to the multivariate Cox regression model, only HBeAg positivity (hazard ratio [HR], 0.39; 95% confidence interval [CI], 0.26 to 0.59;P< 0.001) and a high baseline HBV DNA level (HR, 0.44; 95% CI, 0.29 to 0.67;P< 0.001) had a significant influence on the time to a CVR. The similar cumulative CVR rates during the follow-up show that TDF has comparable efficacy in lamivudine-experienced and NA-naïve patients, and the presence of resistance mutations did not alter the response rates.

1 March 2005 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SKSabahattin Kaymakoglu
Sabahattin Kaymakoglu
CKCetin Karaca
Cetin Karaca
KDKadir Demir
Kadir Demir
SPSule Poturoglu
Sule Poturoglu
ADAhmet Danalioglu
Ahmet Danalioglu
AOAtilla Okten
Atilla Okten
The success of alpha interferon (IFN-α) monotherapy for the treatment of chronic hepatitis D is very limited. In this study, the efficacy of IFN-α and ribavirin combination therapy for chronic hepatitis D was investigated. Nineteen patients (15 males; mean age ± standard deviation, 36.8 ± 12.8 years) with chronic hepatitis D who were treated with IFN-α2b (10 million U, three times/week, subcutaneously) and ribavirin (1,000 to 1,200 mg/day, orally) for 24 months were studied. All patients had compensated liver disease (15 were precirrhotic), elevated transaminase levels, and hepatitis D virus RNA positivity at baseline. Genotypic analyses revealed hepatitis D virus genotype I and hepatitis B virus genotype D. All patients completed the 24 months of treatment and at least 6 months (7 to 19 months) of a follow-up period. Biochemical responses were observed in eight patients (42.1%) at the end of treatment and in seven patients (36.8%) at the end of follow-up. Eight patients (42.1%) at the end of treatment and four patients (21%) at the end of follow-up had virological responses. In conclusion, combination treatment of IFN-α and ribavirin for chronic hepatitis D is not able to induce virological responses at a sufficient rate, despite its partial effectiveness in improving biochemical responses, and is not superior to IFN-α monotherapy.

15 May 2018 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
BABilgehan Aygen
Bilgehan Aygen
ADAhmet Muzaffer Demir
Ahmet Muzaffer Demir
MGMahmut Gumus
Mahmut Gumus
OKOguz Karabay
Oguz Karabay
SKSabahattin Kaymakoğlu
Sabahattin Kaymakoğlu
FTFehmi Tabak
Fehmi Tabak
This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions. Cite this article as: Aygen B, Demir AM, Gümüş M, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turk J Gastroenterol 2018; 29: 259-69.

1 January 2012 in Antiviral Therapy
Verified
Journal Article
Closed access
CKCetin Karaca
Cetin Karaca
OSOzlem Mutluay Soyer
Ozlem Mutluay Soyer
BBBulent Baran
Bulent Baran
AOAsli Cifcibasi Ormeci
Asli Cifcibasi Ormeci
SGSuut Gokturk
Suut Gokturk
SKSabahattin Kaymakoglu
Sabahattin Kaymakoglu
To determine the efficacy of pegylated interferon-α (PEG-IFN-α) therapy for 24 months in chronic delta hepatitis (CDH). Patients with CDH who were treated by PEG-IFN-α2a or -2b for 24 months were included in the study. Demographic, biochemical and virological parameters were recorded at baseline and during follow-up. All included patients completed a treatment period of 24 months and at least a 6 month (range 6-60) follow-up period. Biochemical and virological response rates at end of treatment and end of follow-up were calculated, and predictors of sustained virological response (SVR) were analysed. In total, 32 patients (22 males; mean age ± SD 42.7 ± 12 years) with CDH who were treated with PEG-IFN-α2a (180 µg) or -2b (1.5 µg/kg) once a week subcutaneously for 24 months were included in the study. All patients had compensated liver disease (25 [78%] were non-cirrhotic), increased transaminase levels and HDV RNA positivity at baseline. Genotypic analyses of HDV showed genotype I in all. Mean duration of follow-up was 19.5 months. At the end of treatment, virological response was achieved in 16 (50%) patients. SVR at the end of follow-up was achieved in 15 (47%) patients. A negative HDV RNA at 6 months of treatment was the only predictor of SVR (OR = 20; 95% CI 2, 195; P = 0.01). PEG-IFN-α treatment achieved SVR in approximately half of the patients with CDH, and relapse rate was very low during the follow-up. Negativity of HDV RNA at 6 months may predict SVR in CDH.

1 August 2007 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
SKSabahattin Kaymakoglu
Sabahattin Kaymakoglu
DODilek Oguz
Dilek Oguz
GGGurden Gur
Gurden Gur
SGSelim Gurel
Selim Gurel
ETEthem Tankurt
Ethem Tankurt
AOAtilla Okten
Atilla Okten
Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of <400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.

1 November 2016 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
AOAslı Ormeci
Aslı Ormeci
YAYucel Aydın
Yucel Aydın
ASAbdullah Sumnu
Abdullah Sumnu
BBBulent Baran
Bulent Baran
OSOzlem Mutluay Soyer
Ozlem Mutluay Soyer
SKSabahattin Kaymakoglu
Sabahattin Kaymakoglu
Serum alanine aminotransferase (ALT) is a controversial marker for disease monitoring in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. The aim of this study was to determine the fibrosis stage and histological activity index (HAI) in HBeAg-negative CHB patients with persistently normal ALT (PNALT) and high serum HBV DNA (≥2000 IU/ml) and to investigate clinical risk factors for the requirement of treatment through the examination of liver biopsy specimens. HBeAg-negative CHB patients with PNALT (≤40 IU/l) and high serum HBV DNA (≥2000 IU/ml) were included. HBV fibrosis stage and HAI were scored according to the Ishak system. Multivariate logistic regression analysis was used to estimate the independent risk factors for fibrosis stage ≥2 and/or HAI ≥6. Receiver operating characteristic curve analysis was used to determine an optimal age cut-off for liver biopsy. A total 120 patients were enrolled. These patients had a mean HBV DNA level of 123680±494500 IU/ml; the HBV DNA load was 2000-20000 IU/ml in 68 patients (56.6%) and ≥20000 IU/ml in 52 (43.4%). Eighteen patients (15%) had moderate-to-severe histological activity (HAI ≥6). Forty-three patients (35.9%) had a fibrosis stage ≥2. Forty-eight patients (40%) had a fibrosis stage ≥2 and/or HAI ≥6. On multivariate logistic regression analysis, independent variables associated with fibrosis stage ≥2 and/or HAI ≥6 included age and HBV DNA viral load. Patients with HBV DNA 2000-20000 IU/ml were more likely to require treatment compared to those with a viral load ≥20000 IU/ml. The optimal age cut-off to predict fibrosis stage ≥2 and/or HAI ≥6 was 46 years. Significant liver damage was detected in 40% of CHB patients with PNALT and high HBV DNA upon biopsy. Age and HBV DNA viral load were independent predictors of significant liver damage. A biopsy to determine the degree of liver damage is advisable for CHB patients older than 46 years.